FDA has revised its policy on commercial manufacturers ’ serology tests for #COVID19. Under the new policy, FDA expects commercial manufacturers to submit Emergency Use Authorization (#EUA) requests, including their validation data, within a set timeframe. https://www.fda.gov/news-events/fda-voices/insight-fdas-revised-policy-antibody-tests-prioritizing-access-and-accuracy   … pic.twitter.com/T971fKtRPq

FDA has revised its policy on commercial manufacturers’ serology tests for #COVID19. Under the new policy, FDA expects commercial manufacturers to submit Emergency Use Authorization ( #EUA) requests, including their validation data, within a set timeframe. https://www.fda.gov/news-events/fda-voices/insight-fdas-revised-policy-antibody-tests-prioritizing-access-and-accuracy … pic.twitter.com/T971fKtRPq

Source: Food and Drug Adminstration (FDA): CDRHNew - May 4, 2020 Category: Medical Devices Authors: ( at US_FDA) Source Type: news